BioLife Science Breast Cancer Vaccines
Breast cancer is one of the major malignant diseases in Western countries. Although great achievements in treatment of this disease have been made during the last decades, breast cancer is still one of the most common causes of death of women.
In recent years advances in molecular biology lead to the development of many novel concepts of tumor therapy promising superior efficacy and less side effects. One of these strategies is tumor vaccination. Tumor vaccines are compounds that trigger an immune reaction directed toward the tumor cells which should eventually lead to the destruction of the tumor by the patient's immune system.
This section is divided into four parts:
Background: A brief review on recent developments in breast cancer treatment including some information on HER-2, the target of our breast cancer vaccines.
Tumor vaccines: A description of possible mechanisms of action of tumor vaccines.
HerVac®: Our breast cancer vaccine based on immunogenic peptides from the surface of the HER-2 protein.
MimoVac®: A novel concept of vaccine development based on peptides mimicking natural antibody binding sites (mimotopes).